Nano-C’s Unique Chemistry is a Key Enabler for Unprecedented Potential Drug Efficacy in Broad Range of Treatments
Westwood, MA July 21, 2020 — Nano-C, Inc, a leading producer of patented specialty active ingredients and formulations, announces a signed Letter of Intent (LOI) to pursue a strategic partnership with Unify Pharmaceuticals, a Vanderbilt University spinout co-founded by Dr. Laura Dugan (Vanderbilt, Washington University, Stanford, MIT). Unify is set to begin Phase 1 clinical trials this year for drug therapies for neurodegenerative disease as well as fast-track clinical trials for treatment of COVID-19.
Nano-C and Unify have had a growing and active business relationship for several years and are pleased to formalize their strategic partnership. As Unify’s chemistry partner Nano-C will manage the scale up and synthesis of a functionalized fullerene identified as UP-1007, Unify’s active pharmaceutical ingredient (API), at an exacting cGMP standard. Nano-C and Unify intend to execute a Contract Manufacturing and Supply Agreement covering the preparation for and completion of Phase I and fast-track clinical trials.
Dr. Dugan has studied the therapeutic properties of functionalized fullerenes for over 20 years and has published numerous scientific papers on the potential benefits of these unique APIs on neurodegenerative disease including Parkinson’s and Alzheimer’s. Pre-clinical trials showed marked efficacy on primates afflicted with Parkinson’s Disease, with statistically significant differences appearing after just 30 days vs the control with no toxicity over the course of the trial. Data from Dr. Dugan’s research is being leveraged for a possible COVID-19 drug therapy.
Fullerenes are small molecules that can be customized for use in a wide range of therapeutic applications. Their versatility stems from their fundamental molecular properties and by applying functional chemistry to their surface, they become a true molecular platform that potentially enables strong anti-viral and anti-inflammatory properties to affect a new class of therapeutics.Nano-C and Unify are in the process of negotiating a term sheet to pursue a strategic alliance. This strategic partnership marks Nano-C’s market expansion into biopharmaceuticals and gives Unify access to Nano-C’s leading-edge organic chemists for the optimization of UP-1007 and next generation APIs, and at the volumes and quality required during the clinical trial phase and into commercialization.
About Nano-C, Inc.
Nano-C is a leading innovator and manufacturer in the chemistry of nanostructured carbon, including fullerenes, carbon nanotubes (CNT), and their chemical derivatives. Nano-C is focused on fundamental technology trends: the roll-out of 5G, connectivity driven by the Internet of Things, the race to extend Moore’s Law, the move to address climate change through sustainable energy generation and now healthcare. Proprietary materials produced by Nano-C are critical links in the value chain for next-generation electronics, sensors, semiconductor manufacturing and biopharmaceuticals. Nano-C’s advanced materials and molecular platform encompasses a portfolio of unique solutions protected by over 150 global patents across 46 patent families. Through its patented products and processes, and its distinct competencies in the chemistry of these materials, Nano-C is enabling a revolution in device design, manufacture, and performance, and it is committed to their responsible development and use.
About Unify Pharmaceuticals
Unify Pharmaceuticals is a biotech company utilizing the latest scientific discoveries to develop drugs targeting neurodegenerative diseases such as Parkinson’s Disease, Myocardial Infarction, Macular Degeneration, Alzheimer’s and Strokes. The company is the culmination of over 20 years’ research into UP-1007 and related molecules. UP-1007 is the first-in-class water-soluble fullerene that has been shown to successfully address the underlying causes of Parkinson’s and other diseases involving oxidative damage. For more information please visit https://unifypharma.com/.
Comments are closed.